BlossomHill (BLSM) 10% Owner Cui Jingrong Receives Award & Converts Preferred

What Happened

• Cui Jingrong Jean, reported as a 10% owner of BlossomHill Therapeutics (BLSM), was granted 676,205 derivative shares on Aug 6, 2026 (reported as $0.00) and on Aug 10, 2026 converted preferred/derivative securities into common stock in three tranches totaling 1,838,896 shares (1,600,682 + 113,435 + 124,779). The conversion entries appear both as acquisitions of common stock and as disposals of the underlying derivative securities, consistent with the automatic conversion of preferred shares into common shares upon the issuer’s IPO closing.

Key Details

• Transaction dates: Grant/award on 2026-08-06; conversions reported on 2026-08-10.
• Prices: Award reported at $0.00 (derivative); conversion entries show N/A for price (automatic conversion per footnote).
• Share counts: 676,205 shares (award); conversions totaling 1,838,896 shares.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Series Angel and Series B Preferred automatically converted 1:1 into common stock at the IPO closing without further consideration.
  • F2: Some shares are held in trust for the Reporting Person and spouse; they are trustees with voting/dispositive power.
  • F3: Reporting person disclaims beneficial ownership of certain securities held by an affiliated entity.
  • F4: The award/option has a vesting schedule (25% vests Aug 6, 2027; remainder vests monthly over 36 months).
• Filing timeliness: Report filed Aug 10, 2026 for transactions starting Aug 6, 2026; filing shows no late-filing notation in this excerpt.

Context

• These entries are derivative-related: the conversions reflect preferred stock being converted into common shares at IPO (not a cash purchase or open-market sale). The Aug 6 award is a derivative grant subject to vesting (see F4), so those shares are not immediately freely tradable. As a 10% owner, this filing documents principal-level holdings and structural conversions rather than routine executive buy/sell decisions; it does not by itself indicate trading sentiment.